StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.13−0.24 (-3.26%)

Close on Nov 17, 2026Market cap $382.38MP/E –Yield –

Avalo Therapeutics cash

Cash and short-term investments held at the end of each period.

Avalo Therapeutics's cash was $472.20M at Jun 30, 2026. For fiscal 2025 it was $98.30M, down 27.0% from the year before. Over ten years it grew 16.6% a year on average. The highest annual figure on record is $134.70M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$98.30M-27.0%
FY2024Dec 31, 2024$134.70M+1684.8%
FY2023Dec 31, 2023$7.55M-43.3%
FY2022Dec 31, 2022$13.32M-75.7%
FY2021Dec 31, 2021$54.86M+187.2%
FY2020Dec 31, 2020$19.11M+412.4%
FY2019Dec 31, 2019$3.73M-65.3%
FY2018Dec 31, 2018$10.75M+312.5%
FY2017Dec 31, 2017$2.61M-49.9%
FY2016Dec 31, 2016$5.20M-75.4%
FY2015Dec 31, 2015$21.16M+80.2%
FY2014Dec 31, 2014$11.74M+243.2%
FY2013Dec 31, 2013$3.42M-64.1%
FY2012Dec 31, 2012$9.52M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$472.20M+316.8%
Q1 FY2026Mar 31, 2026$82.00M-34.4%
Q4 FY2025Dec 31, 2025$98.30M-27.0%
Q3 FY2025Sep 30, 2025$111.60M+36.3%
Q2 FY2025Jun 30, 2025$113.30M+21.3%
Q1 FY2025Mar 31, 2025$125.05M+13.5%
Q4 FY2024Dec 31, 2024$134.70M+1684.8%
Q3 FY2024Sep 30, 2024$81.86M+704.1%
Q2 FY2024Jun 30, 2024$93.43M+1381.3%
Q1 FY2024Mar 31, 2024$110.18M+560.3%
Q4 FY2023Dec 31, 2023$7.55M-43.3%
Q3 FY2023Sep 30, 2023$10.18M-39.9%
Q2 FY2023Jun 30, 2023$6.31M-43.9%
Q1 FY2023Mar 31, 2023$16.69M-56.6%
Q4 FY2022Dec 31, 2022$13.32M-75.7%
Q3 FY2022Sep 30, 2022$16.94M-76.3%
Q2 FY2022Jun 30, 2022$11.25M-72.2%
Q1 FY2022Mar 31, 2022$38.47M+0.5%
Q4 FY2021Dec 31, 2021$54.86M+187.2%
Q3 FY2021Sep 30, 2021$71.51M+114.1%
Q2 FY2021Jun 30, 2021$40.44M-10.9%
Q1 FY2021Mar 31, 2021$38.29M+576.7%
Q4 FY2020Dec 31, 2020$19.11M+412.4%
Q3 FY2020Sep 30, 2020$33.39M+535.9%
Q2 FY2020Jun 30, 2020$45.39M+383.6%
Q1 FY2020Mar 31, 2020$5.66M-64.9%
Q4 FY2019Dec 31, 2019$3.73M-65.3%
Q3 FY2019Sep 30, 2019$5.25M-23.2%
Q2 FY2019Jun 30, 2019$9.39M+330.6%
Q1 FY2019Mar 31, 2019$16.12M+538.7%
Q4 FY2018Dec 31, 2018$10.75M+312.5%
Q3 FY2018Sep 30, 2018$6.84M-71.5%
Q2 FY2018Jun 30, 2018$2.18M-60.1%
Q1 FY2018Mar 31, 2018$2.52M-15.9%
Q4 FY2017Dec 31, 2017$2.61M-49.9%
Q3 FY2017Sep 30, 2017$23.96M+171.8%
Q2 FY2017Jun 30, 2017$5.46M–
Q1 FY2017Mar 31, 2017$3.00M–
Q4 FY2016Dec 31, 2016$5.20M–
Q3 FY2016Sep 30, 2016$8.82M–

More Avalo Therapeutics figures

See a number that looks wrong?